Scientists are accelerating efforts to develop a vaccine against the deadly hantavirus following an outbreak aboard the MV Hondius cruise ship, which reportedly resulted in three fatalities. At present, there is no approved vaccine or specific treatment for the virus, which can become severe and life-threatening in some cases.
Researchers at the University of Bath have created a new vaccine antigen aimed at Hantaan disease, a member of the hantavirus family. Early laboratory and animal studies have shown strong immune responses, although large-scale human clinical trials are still needed before the vaccine can be approved for public use.
Professor Asel Sartbaeva noted that an effective vaccine could play an important role in preventing outbreaks or reducing the severity of infections. For now, treatment mainly focuses on early medical intervention to improve survival rates.
Initial symptoms of hantavirus often resemble common illnesses such as flu or COVID-19, including fever, fatigue, and muscle aches. In more severe cases, the disease can progress rapidly, leading to breathing difficulties, kidney complications, and the need for intensive care such as oxygen support, dialysis, or mechanical ventilation.
The outbreak on the MV Hondius has raised global concern, with investigators still working to determine whether infections occurred onboard or earlier during travel, possibly linked to exposure near wildlife or contaminated areas before departure.
Certain strains of hantavirus can lead to serious conditions such as hantavirus pulmonary syndrome (HPS) or hemorrhagic fever with renal syndrome (HFRS), both of which may cause organ failure. However, not all infections result in severe illness, and some individuals may remain asymptomatic.
Researchers are also exploring innovative vaccine technologies, including a heat-stable delivery method known as ensilication, which could improve vaccine storage and transport. This approach may eventually allow rapid distribution—potentially even via drones—during future outbreaks.
